Diabetic KetoacidosisPhase 2NCT03717896
Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis
A Phase 2 study testing 200mg IV thiamine in 50mL 0.9% saline in people with Diabetic Ketoacidosis, run by Beth Israel Deaconess Medical Center at 1 site in United States.
Trial summary
This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Ketoacidosis
- What is being tested?
- 200mg IV thiamine in 50mL 0.9% saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 102 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Nov 2018to 1 Oct 2024
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Bicarbonate ≤15 mEq/L
- Anion gap > 12 mEq/L
- Blood pH≤ 7.24 (if already obtained by clinical team)
- Urine ketones (qualitative) or serum ketones (β-hydroxybutyric acid) > 3 mmol/L
- Enrollment within 6 hours of presentation
Who cannot join
- Current thiamine supplementation ≥ 6 milligrams per day (i.e., more than a multivitamin)
- Competing causes of severe acidosis including seizure, carbon monoxide poisoning, cyanide toxicity, cardiac arrest, liver dysfunction (specifically defined as known cirrhosis)
- Known allergy to thiamine
- Competing indication for thiamine administration as judged by the clinical team (e.g., significant alcohol use)
- Research-protected populations (pregnant women and prisoners)
- Patient enrolled previously in same study
- Code status of Do Not Resuscitate/Do Not Intubate (DNR/DNI) or Comfort Measures Only (CMO)
Trial locations and contacts
1 site in 1 country.
United States1 site
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
About this study
This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (ICU) and hospital stay or decreases hospital resource utilization.
Read the detailed description
Thiamine (vitamin B1) is a water-soluble vitamin that plays a key role in aerobic glucose metabolism. Thiamine is a cofactor of pyruvate dehydrogenase (PDH), an enzyme that must be activated for entry into the Krebs Cycle for aerobic metabolism. PDH activity is reduced in thiamine deficient states, resulting in a shift in pyruvate metabolism to the anaerobic pathway. This leads to increased lactate production and acidosis. Thiamine loss in the urine, with consequent thiamine deficiency, is not uncommon in diabetes. The investigators' preliminary studies have found that thiamine deficiency in occurs in as many as 39% of patients with DKA, and that thiamine levels are inversely associated with lactate and acidosis. The investigator hypothesizes that treating DKA patients with intravenous thiamine will lead to faster resolution of acidosis and improved aerobic metabolism. The investigator's secondary hypothesis is that thiamine treatment will shorten stays in the ICU and hospital and lead to utilization of fewer hospital resources.
In this randomized, double-blind, placebo-controlled trial, patients admitted to the hospital with DKA who are enrolled in the study will be randomized to either intravenous thiamine (200mg in 0.9% saline) twice daily for two days or an identical volume of 0.9% saline on the same schedule. The investigator's primary outcome is change in bicarbonate over the 24 hours following enrollment, with measurements at 0, 6, 12, 18, 24 hours, using a linear mixed-effects model. Secondarily, patients will be stratified by Type I and Type II DM. Additionally, a pre-planned sub-analysis of thiamine deficient subjects will be performed.
- Conditions
- Diabetic Ketoacidosis
- Being tested
- 200mg IV thiamine in 50mL 0.9% saline, Placebo
- Keywords
- diabetic ketoacidosis, DKA, thiamine, acidosis, oxygen consumption, lactate
- Medical subject headings
- Diabetic Ketoacidosis, Acidosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
200mg IV thiamine in 50mL 0.9% salineDrug
Also called Vitamin B1
Thiamine 200mg IV every 12 hours for 2 days
PlaceboDrug
50mL 0.9% saline
| Study group | Role | What they receive |
|---|---|---|
| Thiamine | Experimental | 200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days Receives: Drug: 200mg IV thiamine in 50mL 0.9% saline |
| Placebo | Placebo comparator | 100mL 0.9% saline twice daily for two days Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma Bicarbonate Levels
Primary outcome of plasma bicarbonate levels over 24 hours (6, 12, 18, 24 hours) following enrollment
Measured: 6, 12, 18, and 24 hours after enrollment
Secondary outcomes (18)
Lactate
Secondary outcome of lactate over 24 hours (6, 12, 18, 24 hours) following enrollment
Measured: 6, 12, 18, and 24 hours after enrollment
Anion Gap
Secondary outcome of anion gap over 24 hours (6, 12, 18, 24 hours) following enrollment
Measured: 6, 12, 18, and 24 hours after enrollment
ICU Length of Stay
ICU length of stay reflects the number of ICU admission days.
Measured: 45 days
Hospital Length of Stay
Hospital length of stay reflects how long it takes a diabetic ketoacidosis patient to recover to the point where he/she can be released from the hospital.
Measured: 45 days
Duration of Insulin Therapy
The duration of insulin therapy is calculated by examining the hospital clinical information systems for all records of IV insulin infusion beginning at the time of enrollment. The start and the stop time-stamps of medication infusion are used to calculate a duration of infusion.
Measured: First 7 days after enrollment
SOFA Score (Sequential Organ Failure Assessement Score)
The SOFA score is a validated measure of organ dysfunction commonly used in critically ill patients, particularly those with sepsis. It evaluates the function of six organ systems-respiratory, cardiovascular, neurologic, hepatic, renal, and coagulation-based on routinely collected clinical and laboratory data. Each organ system is assigned a score from 0 (normal function) to 4 (most severe dysfunction), resulting in a total score ranging from 0 to 24. Higher SOFA scores indicate greater severity of organ failure and a higher risk of adverse outcomes. SOFA score in this study uses a modification in which the arterial oxygen saturation/fraction of inspired oxygen (SaO2 /FiO2) ratio is substituted for the partial pressure of arterial oxygen/fraction of inspired oxygen (PaO2 /FiO2 ratio).
Measured: 24 hours
Oxygen Consumption by Circulating Mononuclear Cells
Oxygen consumption rate of circulating peripheral blood mononuclear cells measured using Seahorse. Basal respiration represents oxygen consumption under baseline conditions. ATP-linked respiration represents oxygen consumption coupled to ATP production, while proton leak represents oxygen consumption not linked to ATP synthesis. Maximal respiration represents the maximal capacity of the electron transport chain after uncoupling. Spare respiratory capacity represents the difference between maximal and basal respiration and indicates the ability to respond to increased energy demand. Non-mitochondrial respiration represents oxygen consumption independent of mitochondrial activity.
Measured: 24 hours
Pyruvate Dehydrogenase Activity
Secondary outcome of change in PDH specific activity over 72 hours or at discharge if patient's hospital length of stay was less than 72 hours. PDH activity and total PDH protein quantity were measured in isolated peripheral blood mononuclear cells (PBMCs) following selective disruption of the mitochondrial membrane, using a previously validated immunocapture and microplate-based enzymatic assay protocol. PDH-specific activity was calculated as the ratio of measured PDH enzymatic activity to the natural logarithm of PDH protein quantity (PDH activity / ln[PDH quantity]), providing a normalized metric that reflects the functional efficiency of the enzyme independent of its expression level. Higher values suggest higher enzymatic efficiency.
Measured: 24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)
Neurocognitive: Hopkins Verbal Learning Test - Total Recall
The Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall score is a measure of verbal learning and immediate memory. Participants are read a list of 12 words (from three semantic categories) and asked to recall as many words as possible across three consecutive learning trials. The Total Recall score is calculated as the sum of correctly recalled words across the three trials, yielding a possible range of 0 to 36, with higher scores indicating better verbal learning and memory performance. This score reflects both initial acquisition and short-term retention of verbal information and is commonly used to assess cognitive function in clinical research.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Hopkins Verbal Learning Test - Delayed Recall
The Hopkins Verbal Learning Test-Revised (HVLT-R) Delayed Recall score assesses retention of verbal information after a delay. Following completion of the three learning trials, participants are asked to recall the previously presented word list after a delay period (typically 20-25 minutes) without re-exposure to the words. The Delayed Recall score is calculated as the number of correctly recalled words, with a possible range of 0 to 12, where higher scores indicate better memory retention. This measure reflects the ability to consolidate and retrieve learned information over time and is commonly used to evaluate memory function in clinical and research settings.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Hopkins Verbal Learning Test - Retention
The Hopkins Verbal Learning Test-Revised (HVLT-R) Retention (%) score reflects the proportion of learned information that is retained over a delay. It is calculated as the ratio of the Delayed Recall score to the highest number of words recalled on any of the three immediate recall trials, multiplied by 100, yielding a percentage value. Scores typically range from 0% to 100%, with higher values indicating better retention of previously learned material. This measure provides an index of memory retention independent of initial learning performance.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Hopkins Verbal Learning Test - Recognition Discrimination Index
The Hopkins Verbal Learning Test-Revised (HVLT-R) Recognition Discrimination Index assesses recognition memory by evaluating the ability to distinguish previously learned words from novel distractors. During the recognition phase, participants are presented with a list of target words and distractor words and asked to identify those that were previously learned. The Recognition Discrimination Index is calculated as the number of true positives (correctly identified target words) minus the number of false positives (incorrectly identified distractor words), yielding a score typically ranging from -12 to 12. Higher scores indicate better recognition accuracy and discrimination ability, reflecting the integrity of memory retrieval processes.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Brief Visuospatial Memory Test
The Brief Visuospatial Memory Test (BVMT) assesses visuospatial learning and memory. Participants are shown six geometric designs for a brief period and asked to reproduce them from memory across three learning trials. Performance is scored based on the accuracy and placement of each design, with a total recall score ranging from 0 to 36, where higher scores indicate better visuospatial memory. A delayed recall trial is administered after a delay to assess retention of visual information. This measure evaluates the ability to encode, store, and retrieve visuospatial material.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Trail Making Test - Test Part A
The Trail Making Test Part A (TMT-A) assesses visual attention, processing speed, and psychomotor function. Participants are instructed to connect numbered circles in sequential order as quickly as possible. The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance. There is no fixed maximum score, although testing is typically discontinued at a predefined time limit (commonly 300 seconds).
Measured: At hospital discharge, median of 4 days
Neurocognitive: Trail Making Test - Test Part B
The Trail Making Test Part B (TMT-B) assesses executive function, including cognitive flexibility and set-shifting, in addition to processing speed. Participants are required to alternate between numbers and letters in sequence (e.g., 1-A-2-B) as quickly as possible. The primary outcome is the time to completion, measured in seconds, with lower times indicating better performance. As with TMT-A, there is no fixed maximum score, and testing is typically discontinued at a predefined time limit (commonly 300 seconds).
Measured: At hospital discharge, median of 4 days
Neurocognitive: WAIS-IV Digit Span
The Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Digit Span subtest assesses attention, working memory, and concentration. Participants are asked to repeat sequences of numbers in forward order (Digit Span Forward), reverse order (Digit Span Backward), and ascending order (Digit Span Sequencing). Scores are based on the total number of correctly recalled sequences, with higher scores indicating better attention and working memory capacity. The total score ranges from 0 to 48.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Test of Verbal Fluency and Animal Naming
The Animal Naming test is a measure of semantic verbal fluency and executive function. Participants are asked to name as many animals as possible within a fixed time period. The score is the total number of unique, correct animal names generated, with higher scores indicating better semantic memory retrieval and executive functioning. Scores range from 0 with no fixed upper limit.
Measured: At hospital discharge, median of 4 days
Neurocognitive: Test of Premorbid Functioning
The Test of Premorbid Functioning (TOPF) estimates an individual's baseline cognitive ability prior to illness or injury. Participants are asked to read aloud a list of irregularly spelled words, and performance is scored based on correct pronunciation. Scores are used to estimate premorbid intellectual functioning. Scores range from 0 to 70, with higher scores indicating higher estimated premorbid functioning. This measure helps contextualize current cognitive performance relative to expected baseline levels.
Measured: At hospital discharge, median of 4 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2018
- Study start21 Nov 2018
- Primary completion30 Sep 2024
- Study completion1 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Diabetic KetoacidosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 102 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael Donnino, Beth Israel Deaconess Medical Center
- Investigators
- Michael Donnino, MD, Principal investigator, Beth Israel Deaconess Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03717896
- Sponsor's protocol ID
- 2018P000475
- Other IDs
- 1R01DK112886-01A1
- Status last verified
- Apr 2026
- First submitted
- 22 Oct 2018
- Last updated
- 23 Jun 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Vine J, Mehta S, Balaji L, Berg KM, Berlin N, Liu X, Ngo L, Shea M, Moskowitz A, Donnino MW, Grossestreuer AV. Thiamine as adjunctive therapy for diabetic ketoacidosis (DKAT) trial protocol and statistical analysis plan: a prospective, single-centre, double-blind, randomised, placebo-controlled clinical trial in the USA. BMJ Open. 2024 Feb 29;14(2):e077586. doi: 10.1136/bmjopen-2023-077586.
PubMed 38423765
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Thiamine as Adjunctive Therapy for Diabetic Ketoacidosis
- ClinicalTrials.gov ID
- NCT03717896
- Acronym / sponsor ID
- 2018P000475
- Conditions
- Diabetic Ketoacidosis
- Keywords
- diabetic ketoacidosis, DKA, thiamine, acidosis, oxygen consumption, lactate
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 102 participants (actual)
- Lead sponsor
- Beth Israel Deaconess Medical CenterUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 21 Nov 2018 (actual)
- Primary completion
- 30 Sep 2024 (actual)
- Study completion
- 1 Oct 2024 (actual)
- First posted
- 24 Oct 2018 (actual)
- Results
- Posted 23 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (ICU) and hospital stay or decreases hospital resource utilization.
Detailed description
Thiamine (vitamin B1) is a water-soluble vitamin that plays a key role in aerobic glucose metabolism. Thiamine is a cofactor of pyruvate dehydrogenase (PDH), an enzyme that must be activated for entry into the Krebs Cycle for aerobic metabolism. PDH activity is reduced in thiamine deficient states, resulting in a shift in pyruvate metabolism to the anaerobic pathway. This leads to increased lactate production and acidosis. Thiamine loss in the urine, with consequent thiamine deficiency, is not uncommon in diabetes. The investigators' preliminary studies have found that thiamine deficiency in occurs in as many as 39% of patients with DKA, and that thiamine levels are inversely associated with lactate and acidosis. The investigator hypothesizes that treating DKA patients with intravenous thiamine will lead to faster resolution of acidosis and improved aerobic metabolism. The investigator's secondary hypothesis is that thiamine treatment will shorten stays in the ICU and hospital and lead to utilization of fewer hospital resources.
In this randomized, double-blind, placebo-controlled trial, patients admitted to the hospital with DKA who are enrolled in the study will be randomized to either intravenous thiamine (200mg in 0.9% saline) twice daily for two days or an identical volume of 0.9% saline on the same schedule. The investigator's primary outcome is change in bicarbonate over the 24 hours following enrollment, with measurements at 0, 6, 12, 18, 24 hours, using a linear mixed-effects model. Secondarily, patients will be stratified by Type I and Type II DM. Additionally, a pre-planned sub-analysis of thiamine deficient subjects will be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Thiamine | Experimental | Drug: 200mg IV thiamine in 50mL 0.9% saline200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days |
| Placebo | Placebo comparator | Drug: Placebo100mL 0.9% saline twice daily for two days |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Bicarbonate ≤15 mEq/L
- Anion gap > 12 mEq/L
- Blood pH≤ 7.24 (if already obtained by clinical team)
- Urine ketones (qualitative) or serum ketones (β-hydroxybutyric acid) > 3 mmol/L
- Enrollment within 6 hours of presentation
Key exclusion criteria (7 listed)
- Current thiamine supplementation ≥ 6 milligrams per day (i.e., more than a multivitamin)
- Competing causes of severe acidosis including seizure, carbon monoxide poisoning, cyanide toxicity, cardiac arrest, liver dysfunction (specifically defined as known cirrhosis)
- Known allergy to thiamine
- Competing indication for thiamine administration as judged by the clinical team (e.g., significant alcohol use)
- Research-protected populations (pregnant women and prisoners)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 200mg IV thiamine in 50mL 0.9% salineAlso: Vitamin B1Thiamine 200mg IV every 12 hours for 2 days | Drug | Thiamine |
| Placebo50mL 0.9% saline | Drug | Placebo |
Primary outcome
Plasma Bicarbonate Levels
Time frame: 6, 12, 18, and 24 hours after enrollment
Primary outcome of plasma bicarbonate levels over 24 hours (6, 12, 18, 24 hours) following enrollment
18 secondary outcomes
Lactate
Time frame: 6, 12, 18, and 24 hours after enrollment
Anion Gap
Time frame: 6, 12, 18, and 24 hours after enrollment
ICU Length of Stay
Time frame: 45 days
Hospital Length of Stay
Time frame: 45 days
Duration of Insulin Therapy
Time frame: First 7 days after enrollment
SOFA Score (Sequential Organ Failure Assessement Score)
Time frame: 24 hours
Oxygen Consumption by Circulating Mononuclear Cells
Time frame: 24 hours
Pyruvate Dehydrogenase Activity
Time frame: 24 hours and 72 hours (or at discharge if hostpial length of stay was less than 72 hours)
Neurocognitive: Hopkins Verbal Learning Test - Total Recall
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Hopkins Verbal Learning Test - Delayed Recall
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Hopkins Verbal Learning Test - Retention
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Hopkins Verbal Learning Test - Recognition Discrimination Index
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Brief Visuospatial Memory Test
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Trail Making Test - Test Part A
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Trail Making Test - Test Part B
Time frame: At hospital discharge, median of 4 days
Neurocognitive: WAIS-IV Digit Span
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Test of Verbal Fluency and Animal Naming
Time frame: At hospital discharge, median of 4 days
Neurocognitive: Test of Premorbid Functioning
Time frame: At hospital discharge, median of 4 days
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38423765Vine J, Mehta S, Balaji L, Berg KM, Berlin N, Liu X, Ngo L, Shea M, Moskowitz A, Donnino MW, Grossestreuer AV. Thiamine as adjunctive therapy for diabetic ketoacidosis (DKAT) trial protocol and statistical analysis plan: a prospective, single-centre, double-blind, randomised, placebo-controlled clinical trial in the USA. BMJ Open. 2024 Feb 29;14(2):e077586. doi: 10.1136/bmjopen-2023-077586.
- Individual participant dataSharing planned: No
Related trials for Diabetic Ketoacidosis
Not yet recruitingPhase 2
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM)
RecruitingObservational study
Perfusion Index for Predicting Diabetic Ketoacidosis Severity in the Emergency Department
Diabetic Ketoacidosis
Not yet recruitingObservational study
Leukocyte Glucose Index and Severity of Diabetic Ketoacidosis
Diabetic Ketoacidosis, Diabetes Mellitus
Not yet recruiting
The BRIGHT Study (Device Name: HALO System)
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
RecruitingPhase 4
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
Ketosis Prone Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Donnino, MD principal investigator
Beth Israel Deaconess Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing 200mg IV thiamine in 50mL 0.9% saline in people with Diabetic Ketoacidosis, run by Beth Israel Deaconess Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma Bicarbonate Levels (time frame: 6, 12, 18, and 24 hours after enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03717896, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026; AzTrials last refreshed its copy on 26 Oct 2026.